Aggressive ovarian tumors begin as malignant cells kept in check by the immune system until, suddenly and unpredictably, they explode into metastatic cancer. New findings from scientists at The Wistar Institute demonstrate that ovarian tumors don't necessarily break "free" of the immune system, rather dendritic cells of the immune system seem to actively support the tumor's escape...

A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer. Prof. Kapelushnik of BGU's Faculty of Health Sciences and his team developed a device that illuminates cancer cells with less than a teaspoon of blood...

Ovarian cancer, which killed 15,000 American women last year, is one of the deadliest forms of cancer. A team of Wayne State University School of Medicine researchers recently proved that freezing tumors increases survival rates in ovarian cancer patients. The "freeze and destroy" technique is an alternative for local treatment of cancerous tumors, said Peter Littrup, M.D...

Highly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients, an international team of researchers led by scientists at The University of Texas MD Anderson Cancer center reports in the New England Journal of Medicine...

According to a study published in the journal Radiology, researchers from Cancer Research UK's Cambridge Experimental Cancer Medicine Center at the University of Cambridge, have determined that the best method to monitor how women with late-stage ovarian cancer are responding to treatment may be a magnetic resonance imaging (MRI) technique...

Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to "anti-angiogenic" drugs that block blood vessel formation...

There is a need to analyze tumor specimens at the time of ovarian cancer recurrence, according to a new study published in Molecular Cancer Therapeutics. Researchers used a diagnostic technology called molecular profiling to examine the differences in the molecular characteristics of primary and recurrent ovarian tumors and found significant changes for some biomarkers...

Man may not live by bread alone, but cancer in animals appears less resilient, judging by a study that found chemotherapy drugs work better when combined with cycles of short, severe fasting. Even fasting on its own effectively treated a majority of cancers tested in animals, including cancers from human cells...

In a study conducted by researchers at Moffitt Cancer Center and colleagues from 11 other institutions in the Unites States and the United Kingdom, genes that are known to be involved in inflammation were found to be related to risk of ovarian cancer. Their study appeared in a recent issue of Cancer Research, published by the American Association for Cancer Research...

1...

Ovarian cancer is a major cause of death worldwide. Approximately 25,000 women will be diagnosed with ovarian cancer this year and 15,000 women will die from it in the United States alone. The novel anti-cancer drug diindolylmethane (DIM) has been shown in laboratory to inhibit the growth of ovarian cancer cells...

The use of symptom indices to identify patients with symptoms associated with ovarian cancer who may need further screening is increasing in both the UK and the US in an attempt to promote earlier diagnosis, but they may need to be reassessed in order to help better detect cancer, according to a study published January 13 in the Journal of the National Cancer Institute...

OHSU Knight Cancer Institute study results suggest that more patients than initially thought could potentially be treated with a new class of drugs, PARP inhibitors A constellation of defective proteins suspected in causing a malfunction in the body's ability to repair its own DNA could be the link scientists need to prove a new class of drugs will be effective in treating a...

A study published January 13 in the Journal of the National Cancer Institute reveals that in the UK and the U.S., symptom indices used to identify individuals with symptoms connected with ovarian cancer who may need additional screening is on the rise, however, in order to help better detect cancer they may need to be reevaluated...

The lives of hundreds of women could be saved every year, thanks to a simple online calculator that could help GPs identify women most at risk of having ovarian cancer at a much earlier stage. Academics from The University of Nottingham and ClinRisk Ltd have developed a new QCancer algorithm using the UK QResearch database...

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer...

Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK...

Roche announced today that its product known as Avastin (bevacizumab) has been approved by the European Union for treatment of ovarian cancer. When used in combination with standard chemotherapy (carboplatin and paclitaxel) it will be part of a front-line (first-line following surgery) regime. Hal Barron M.D...

According to a novel phase II randomized study published Online First in The Lancet Oncology, a new anti-VEGF drug aflibercept that obstructs the action of vascular endothelial growth factor (VEGF) can prevent malignant ascites (excessive fluid in the abdomen that contains cancer cells), a prevalent and painful complication of advanced ovarian cancer from developing...

The cancer-causing potential of fetal exposure to carcinogens can vary substantially, a recent study suggests, causing different types of problems much later in life depending on the stage of pregnancy when the fetus is exposed. The research sheds further light on the way in which toxic damage early in life can later manifest themselves as cancer, due to "epigenetic" changes in cells...